Study of vitiligo repigmentation with systemic and topical unani formulations – an open label clinical study

Vitiligo affects about 0.1–8% of the world population [1]; being a cosmetic problem needs more attention as it leads to social isolation and psychological discomfort [2]. The efficacy of compound Unani formulation UNIM 004 and UNIM 005 (coded) both systemic and topical was studied in an open label study. 2020 patients were treated and evaluated for their regimentation pattern in relation to different clinical types of Vitiligo as non dermatomal, acrofacial and mixed Vitiligo (Generalized), segmental, mucosal and focal Vitiligo (localized) and were evaluated initially after 3 months and subsequently once in 2 months for total period of 9 months. Response to the treatment was recorded as follicular and peri-lesional repigmentation in relation to age, duration of disease, extention and distribution of lesions. The Mixed and nondermatomal Vitiligo has responded well 41.11±19.65 and 39.50±18.69 mean percent of repigmentation respectively (p<0.001) than acrofacial Vitiligo 35.17±19.50 among generalized type, whereas focal and segmental Vitiligo had responded better i.e. 42.72±23.26 and 36.20±18.93 mean percent of repigmentation respectively which is better than mucosal Vitiligo 34.55±19.15 among localized type (p<0.05).

References: [1] Alikhan A, Felsten LM, Daly, M, Petronic-Rosic V (2011) Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differenzial diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 65(3):473–91 [2] Ongenae K, Beelaert L, van Geel N, Naeyaert, JM (2006) psychosocial effects of Vitiligo. J Eur Acad Dermatol Venereol. 20(1):1–8